New York, June 5, 2026, 10:04 (EDT)
AVITA Medical shares edged higher on Friday after stockholders backed a package of board, pay and financing measures, including director equity awards and warrants tied to a lender, shifting attention to how the wound-care company funds its next phase of growth. The stock was up 0.8% at $4.395 in early U.S. trading, according to a Cboe BZX estimate carried by MarketScreener.
The vote matters now because AVITA is trying to move from stabilization to steadier execution after a choppy period for reimbursement, the payment system through which insurers or Medicare contractors set how clinicians are paid for using a product. In May, the company said first-quarter revenue rose 4% from a year earlier to $19.3 million and 10% from the prior quarter, and it reaffirmed 2026 revenue guidance of $80 million to $85 million.
The shares are not out of the hole. MarketScreener data showed RCEL up 27.25% so far this year, but down 23.65% over 12 months, a reminder that small medical-device names can move sharply on modest changes in growth expectations. Volume early Friday was thin — meaning fewer shares were changing hands than usual — at about 11,500 shares versus an estimated daily volume of about 229,000.
AVITA said in a June 4 filing that holders of 15.6 million shares voted at its June 3 annual meeting, enough for a quorum. Stockholders elected all seven directors, ratified Grant Thornton as auditor for 2026 and approved lifting the annual cash-fee pool for non-executive directors to $900,000 from $750,000.
Investors also approved equity grants to directors. The awards included restricted stock units, or RSUs — promised shares that vest over time — and stock options, which give the holder the right to buy shares at a set price. A Form 4 showed director Joseph Woody’s grants included 29,446 options with a $3.47 exercise price, subject to shareholder approval obtained on June 3.
The meeting also cleared warrants covering up to 650,000 shares for Perceptive Credit Holdings V, LP, under AVITA’s January credit agreement. Warrants are rights to buy stock in the future; they can help financing partners share in upside, but they may dilute existing holders if exercised.
Cary Vance, president and chief executive, said in AVITA’s May results release that the company had “stabilized the business” and made a “solid start to 2026.” Chief Financial Officer David O’Toole said “Cash receipts lag revenue,” but added that collections and cost discipline gave the company confidence in a significant decrease in second-quarter cash use. AVITA Medical, Inc.
The Street is split, not euphoric. MarketBeat listed a consensus “Hold” rating from six analysts, with three buys, two holds and one sell, and an average 12-month target of $7.25. It also listed Lake Street Capital analyst Frank Takkinen as having upgraded AVITA to Buy from Hold on May 15 and raised the target to $6 from $3.50. MarketBeat
AVITA’s own investor-relations site lists Takkinen among analysts covering the company, along with BTIG’s Ryan Zimmerman, Northland Capital Markets’ Carl Byrnes and TD Cowen’s Josh Jennings. The company says those forecasts are the analysts’ views and not AVITA management’s.
The competitive backdrop is crowded. AVITA’s RECELL system uses a patient’s own skin to create Spray-On Skin cells for burn and trauma wounds, while its U.S. portfolio also includes Cohealyx and PermeaDerm. In broader wound care and biological skin substitutes, market reports list larger or better-known players such as Integra LifeSciences, MiMedx and Organogenesis; that context matters because AVITA is trying to broaden beyond a single RECELL-led revenue base while managing lower gross-margin contributions from newer products.
But the downside case remains plain. AVITA posted a $10.6 million first-quarter net loss, used about $9.9 million in cash during the quarter and ended March with $14.3 million in cash and marketable securities. If collections slow or RECELL utilization does not keep improving, the newly approved warrant and equity capacity could look less like flexibility and more like dilution — more potential shares reducing each existing holder’s ownership claim.
For the week ahead, the stock’s next test is less about the formal vote count and more about execution: whether AVITA can turn its $80 million to $85 million revenue guide into orders, keep cash use down, and show that the portfolio push into RECELL, Cohealyx and PermeaDerm is lifting dollars faster than it weighs on margins.
